Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
10:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Glaukos (GKOS) delivered earnings and revenue surprises of -88.64% and 7.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Corporation (GKOS) CEO Tom Burns on Q2 2022 Results Earnings Call Transcript
09:36pm, Wednesday, 03'rd Aug 2022
Glaukos Corporation (NYSE:GKOS ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - P
The Zacks Analyst Blog Highlights McKesson, AmerisourceBergen, LHC Group and Glaukos
01:07pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
McKesson, AmerisourceBergen, LHC Group and Glaukos are part of Zacks top Analyst Blog.
Medical Device Stocks' Earnings on Aug 3: MCK, ABC & More
02:09pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, ABC, LHCG and GKOS fare this time.
Teleflex (TFX) Q2 Earnings Beat Estimates
11:55am, Thursday, 28'th Jul 2022 Zacks Investment Research
Teleflex (TFX) delivered earnings and revenue surprises of 1.19% and 2.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
11:26am, Thursday, 28'th Jul 2022 Zacks Investment Research
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.
Align Technology (ALGN) Q2 Earnings Lag Estimates, Margins Drop
11:14am, Thursday, 28'th Jul 2022 Zacks Investment Research
The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline
02:28pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
04:49pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
04:46pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
04:18pm, Monday, 25'th Jul 2022 Zacks Investment Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
04:11pm, Monday, 25'th Jul 2022 Zacks Investment Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
03:33pm, Monday, 25'th Jul 2022 Zacks Investment Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
02:29pm, Monday, 25'th Jul 2022 Zacks Investment Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
01:26pm, Monday, 25'th Jul 2022 Zacks Investment Research
Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.
